IGA NEPHROPATHY (IGAN)
Clinical trials for IGA NEPHROPATHY (IGAN) explained in plain language.
Never miss a new study
Get alerted when new IGA NEPHROPATHY (IGAN) trials appear
Sign up with your email to follow new studies for IGA NEPHROPATHY (IGAN), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kidney disease: experimental drug targets Tough-to-Treat IgA nephropathy
Disease control Not yet recruitingThis study tests an experimental drug called SLN12140 in adults with IgA nephropathy, a kidney disease that is not well controlled by current treatments. About 48 participants will receive either the drug or a placebo by injection to see if it can reduce protein in the urine, a s…
Matched conditions: IGA NEPHROPATHY (IGAN)
Phase: PHASE2 • Sponsor: Linno Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 17, 2026 03:39 UTC
-
Herbal granules aim to ease kidney disease in new trial
Disease control Not yet recruitingThis study tests whether Shenqi Yishen Granules, a traditional Chinese medicine, can reduce protein in the urine of adults with IgA nephropathy, a kidney disease. About 102 participants will receive either the granules or a placebo to check safety and effectiveness. The goal is t…
Matched conditions: IGA NEPHROPATHY (IGAN)
Phase: NA • Sponsor: Keda Lu • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New cell shot aims to tame immune attacks on kidneys
Disease control Not yet recruitingThis early-stage trial tests a new cell therapy called GT719 in about 30 adults with kidney diseases caused by the immune system, such as IgA nephropathy and membranous nephropathy. The study has two phases: first, finding a safe dose, then testing that dose in more people. The m…
Matched conditions: IGA NEPHROPATHY (IGAN)
Phase: EARLY_PHASE1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
Engineered immune cells take on tough kidney diseases in first human test
Disease control Not yet recruitingThis early-stage study tests a new treatment for people with severe kidney diseases caused by the immune system attacking the kidneys (lupus nephritis, IgA nephropathy, or membranous nephropathy) that have not responded to standard therapies. The treatment uses specially engineer…
Matched conditions: IGA NEPHROPATHY (IGAN)
Phase: EARLY_PHASE1 • Sponsor: Air Force Military Medical University, China • Aim: Disease control
Last updated May 04, 2026 16:23 UTC
-
New drug tested in kidney patients – no cure, just safety check
Knowledge-focused Not yet recruitingThis early-stage study tests a single injection of RG002C0106 in 24 adults to see how kidney problems affect the drug's safety and processing in the body. Participants include people with normal kidneys and those with mild-to-moderate kidney impairment. The goal is to gather safe…
Matched conditions: IGA NEPHROPATHY (IGAN)
Phase: PHASE1 • Sponsor: Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd. • Aim: Knowledge-focused
Last updated May 13, 2026 15:59 UTC